Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Ogutu, Bernhards R ^a   Apollo, Odika J ^a   McKinney, Denise ^a   Okoth, Willis ^a   Siangla, Joram ^a   Dubovsky, Filip ^b   Tucker, Kathryn ^c   Waitumbi, John N ^a   Diggs, Carter ^d   Wittes, Janet ^c   Malkin, Elissa ^b   Leach, Amanda ^e   Soisson, Lorraine A ^d   Milman, Jessica B ^b   Otieno, Lucas ^a   Holland, Carolyn A ^f   Polhemus, Mark ^a   Remich, Shon A ^a   Ockenhouse, Christian F ^f   Cohen, Joe ^e   Ballou, W Ripley ^e   Martin, Samuel K ^a   Angov, Evelina ^f   Stewart, V Ann ^f   Lyon, Jeffrey A ^f   Heppner Jr , D Gray ^f   Withers, Mark R ^a   more..

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b PATH Malaria Vaccine Initiative   (United States)

^c University of Iowa   (United States)

^d UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^e GSK   (Belgium)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FALCIPARUM MALARIA PROTEIN 1 VACCINE; MALARIA VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG; MEROZOITE SURFACE PROTEIN 1;

ANEMIA; ANTIBODY RESPONSE; ARTICLE; BRAIN MALARIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE PAIN; KENYA; MALARIA; MALARIA FALCIPARUM; PARASITEMIA; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; SKIN DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BLOOD; IMMUNOLOGY; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; TREATMENT FAILURE;

PLASMODIUM FALCIPARUM;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HUMANS; INFANT; KENYA; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; RABIES VACCINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 61849177531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004708     Document Type: Article

References (32)

1. Snow RW, Craig M, Deichmann U, Marsh K (1999) Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ 77(8): 624-640.
2. Gallup JL, Sachs JD (2001) The economic burden of malaria. Am J Trop Med Hyg 64(1-2 Suppl): 85-96.
3. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, et al. (2004) Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71(2 Suppl): 239-247.
4. Alonso PL, Sacarlal J, Aponte JJ, Amanda L, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised, controlled trial. The Lancet 364: 1411-1420.
5. Alonso PL, Sacarlal J, Aponte JJ, Amanda L, Macete E, et al. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. The Lancet 366: 2012-2018.
6. Diggs CL, Ballou WR, Miller LH (1993) The major merozoite surface protein as a malaria vaccine target. Parasitol Today 9: 300-302.
7. Heppner DG, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, et al. (2005) Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23(17-18): 2243-2250.
8. Blackman MJ, Dennis ED, Hirst EM, Kocken CH, Scott-Finnigan TJ, et al. (1996) Plasmodium knowlesi: Secondary processing of the malaria merozoite surface protein-1. Exp Parasitol 83: 229-239.
9. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA (1994) Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 180: 389-393.
10. Corran PH, O'Donnell RA, Todd J, Uthaipibull C, Holder AA, et al. (2004) The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun 72(10): 6185-6189.
11. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, et al. (2004) Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun 72: 1557-1567.
12. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, et al. (1996) Clinical immunity to Plasmodium falciparum malaria is associated with antibodies to the 19-kDa C-terminal fragment of the merozoites surface antigen, PfMSP-1. J Infect Dis 173: 765-769.
13. Stowers AW, Chen L-H, Zhang Y, Kennedy MC, Zou L, et al. (2002) A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci USA 99: 339-344.
14. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, et al. (2005) Clinical grade Plasmodium falciparum FVO MSP1-42 expressed by Escherichia coli protects Aotus nancymai against homologous erythrocytic-stage challenge. Infect Immun 73(1): 287-297.
15. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, et al. (1996) A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 64: 253-261.
16. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP (2002 Mar 15) A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185(6): 820-7.
17. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, Anderson K, Mahakunkijcharoen Y, Martin LB, Wilson D, Elliott S, Elliott S, Eisen DP, Weinberg JB, Saul A, Good MF (2002 Aug 24) Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360(9333): 610-7.
18. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, et al. (2003) Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine. Mol Biochem Parasitol 128: 195-204.
19. Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, et al. (2004) Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22: 3831-3840.
20. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, et al. (2005) Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24: 3009-3017.
21. Stoute JA, Gombe J, Withers MR, Siangla J, Mckinney D, et al. (2005) Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine, Epub ahead of print; in press.
22. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, et al. (2006) Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: Results of a phase I randomized trial. PLoS Clin Trials 1(7): e34.
23. Withers MR, McKinney D, Ogutu BR, Waitumbi J, Milman JB, et al. (2006) Safety and reactogenicity of an MSP_1 malaria vaccine candidate: A randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials 24;1(7): e32.
24. Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, et al. (1999) Longitudinal cohort study of the epidemiology of malaria infections in an area of intense transmission II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 60(4): 641-648.
25. Beier JC, Oster CN, Onyango FK, Bales JD, Sherwood JA, et al. (1994) Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg 50(5): 529-536.
26. Yoon IK, Angov E, Larson D, Heppner DG, Cummings JF, et al. (2005) Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42). Am J Trop Med Hyg 72(6): 714-718.
27. World Health Organization (2000) Severe falciparum malaria. Trans R Soc Trop Med Hyg 94, supplement 1: S1-90.
28. al-Yaman F, Genton B, Kramer KJ, Taraika J, Chang SP, et al. (1995) Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea. Trans R Soc Trop Med Hyg 89: 555-559.
29. al-Yaman F, Genton B, Kramer KJ, Chang SP, Hui GS, et al. (1996) Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 54: 443-448.
30. Shi YP, Sayed U, Qari SH, Roberts JM, Udhayakumar V, et al. (1996) Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun 64: 2716-2723.
31. Braga EM, Barros RM, Reis TA, Fontes CJ, Morais CG, et al. (2002) Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region. Am J Trop Med Hyg 66: 461-466.
32. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ (1997) Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 186(10): 1689-1699.